Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
Adaptive TONIC trial of nivolumab combinations for breast cancer

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.09.17
Views: 952

Dr Marleen Kok - Netherlands Cancer Institute, Amsterdam, Netherlands

Dr Kok speaks with ecancer at ESMO 2017 about early results from TONIC, an adaptive phase II trial of nivolumab after induction for triple negative breast cancer patients.

She outlines the five arms of the trial, and early results from the 55 patients randomised so far, with an overall response rate so far of 24%.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence